Stocks making the biggest moves midday: Paramount Skydance, Wave Lifesciences, Confluent & more

Biotech and tech M&A headlines drove sizable intraday moves: Wave Life Sciences jumped roughly 140% after positive Phase 1 interim data for an RNA obesity shot that reduced fat while preserving muscle, and Structure Therapeutics nearly doubled after reporting up to 11% weight loss at 36 weeks for its obesity pill. Confluent rose ~29% on a Wall Street Journal report that IBM is in advanced talks for an $11 billion acquisition, while Paramount’s hostile bid for Warner Bros. Discovery lifted Paramount ~7% and pushed Netflix down ~4% (Pivotal downgraded Netflix). Other notable moves included Broadcom up ~3% on reports Microsoft may shift custom chips from Marvell (Marvell -10%), CRH +6% and Carvana +12% on S&P 500 inclusion effective Dec. 22, Berkshire shares down >2% after Todd Combs’ departure, CoreWeave -7% on a $2 billion convertible offering, and Five Below +3% on a Truist upgrade.

Analysis

MARKET STRUCTURE: Tech M&A and biotech readouts are creating concentrated, asymmetric winners — short-term beneficiaries are WVE (RNA obesity readout), CFLT (M&A chatter), AVGO (potential MSFT chip supplier) and index-adds CVNA/CRH ahead of Dec 22. Losers include MRVL (potential loss of MSFT business) and CRWV (dilutive $2bn convert), producing sector rotation from small-cap cloud/AI to select M&A/biotech momentum; expect 5–20% intraday moves to persist as deal rumors and trial headlines cascade.

RISK ASSESSMENT: Tail risks are high: Phase‑1 biotech readouts can reverse in later trials (regulatory binary), acquisition rumors can collapse (antitrust/bid failure), and convertible issuance signals dilution that can compress equity. Time horizons: immediate (days) dominated by headline-driven flows and S&P rebalancing; short-term (weeks–months) by M&A outcomes and trial follow-ups; long-term (quarters) by commercialization/earnings. Hidden dependencies include sponsor ability to raise follow‑on capital and index fund mechanical flows.

TRADE IMPLICATIONS: Favor event-driven, delta‑limited exposure: buy-call spreads on WVE and CFLT (3–6 month expiries) rather than outright shares; short MRVL via put spreads or small outright short (size 0.5–1.5% portfolio) given 10–25% downside skew; buy CRH/CVNA pre-Dec 22 to capture index inclusion flows and trim on a 10–15% pop. Use protective collars around core positions and prefer spread structures to limit gamma risk.

CONTRARIAN ANGLES: Consensus may be overpaying for Phase‑1 novelty (WVE) and underpricing dilution risk (CRWV). Netflix’s ~4% decline may be an overreaction if Paramount bid dynamics prolong and advertising/revenue guidance remains intact; consider pair trade long NFLX vs short WBD/para only if additional negative catalysts emerge. Historical parallels: biotech pops after Phase‑1 often retrace 30–60% by pivotal readouts; size accordingly.

Key Decisions for Investors

• Establish a 1–1.5% portfolio allocation to WVE via a 3–6 month call spread (buy near‑the‑money, sell 30–50% OTM) to capture further trial momentum; target +100% upside or cut to a 40% loss within 8–12 weeks if no follow‑up positive headlines.
• Deploy a 1–2% allocation to CFLT by buying 3–6 month calls (or call spreads) to play M&A upside; exit or reduce to zero if no deal announcement within 90 days or if shares drop >25% from current levels.
• Short MRVL sized 0.5–1% via buy‑write/put spread (90–120 day puts) targeting 10–25% downside from current levels on displacement risk; stop‑loss: cover if MRVL recovers 15% or AVGO falls >5% (indicating rumor reversal).
• Buy CVNA and CRH outright 0.5–1% each ahead of S&P inclusion (effective prior to open Dec 22); take profits on a 10–15% rise or exit after inclusion date to capture index flow, whichever occurs first.
• Initiate a 0.5–1% short or buy 3‑6 month put spread on CRWV to express dilution risk after the $2bn convertible offering; target a 20–30% downside within 3 months and tighten if company announces cash‑positive developments.